Free Trial

Uniphar (UPR) Competitors

Uniphar logo
GBX 282 -4.00 (-1.40%)
As of 07:16 AM Eastern

UPR vs. UDG, BTG, ABC, HCM, GNS, INDV, ONT, CLIN, EMIS, and VEC

Should you be buying Uniphar stock or one of its competitors? The main competitors of Uniphar include UDG Healthcare (UDG), BTG (BTG), Abcam (ABC), HUTCHMED (HCM), Genus (GNS), Indivior (INDV), Oxford Nanopore Technologies (ONT), Clinigen Group (CLIN), EMIS Group (EMIS), and Vectura Group (VEC). These companies are all part of the "medical" sector.

Uniphar vs.

Uniphar (LON:UPR) and UDG Healthcare (LON:UDG) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, community ranking, earnings, valuation and analyst recommendations.

In the previous week, Uniphar's average media sentiment score of 0.00 equaled UDG Healthcare'saverage media sentiment score.

Company Overall Sentiment
Uniphar Neutral
UDG Healthcare Neutral

45.3% of Uniphar shares are owned by institutional investors. 10.1% of Uniphar shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Uniphar pays an annual dividend of GBX 2 per share and has a dividend yield of 0.7%. UDG Healthcare pays an annual dividend of GBX 0.17 per share. Uniphar pays out 13.9% of its earnings in the form of a dividend. UDG Healthcare pays out 0.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Uniphar has a net margin of 1.68% compared to UDG Healthcare's net margin of 0.00%. Uniphar's return on equity of 13.18% beat UDG Healthcare's return on equity.

Company Net Margins Return on Equity Return on Assets
Uniphar1.68% 13.18% 3.76%
UDG Healthcare N/A N/A N/A

Uniphar currently has a consensus target price of GBX 310, suggesting a potential upside of 9.93%. Given Uniphar's stronger consensus rating and higher possible upside, equities analysts clearly believe Uniphar is more favorable than UDG Healthcare.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Uniphar
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
UDG Healthcare
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Uniphar has higher revenue and earnings than UDG Healthcare. UDG Healthcare is trading at a lower price-to-earnings ratio than Uniphar, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Uniphar£3.03B0.29£51.04M£14.3819.61
UDG Healthcare£1.25B0.00N/A£25.40N/A

UDG Healthcare received 511 more outperform votes than Uniphar when rated by MarketBeat users. However, 100.00% of users gave Uniphar an outperform vote while only 74.68% of users gave UDG Healthcare an outperform vote.

CompanyUnderperformOutperform
UnipharOutperform Votes
8
100.00%
Underperform Votes
No Votes
UDG HealthcareOutperform Votes
519
74.68%
Underperform Votes
176
25.32%

Summary

Uniphar beats UDG Healthcare on 11 of the 15 factors compared between the two stocks.

Get Uniphar News Delivered to You Automatically

Sign up to receive the latest news and ratings for UPR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

UPR vs. The Competition

MetricUnipharMedical Distribution IndustryMedical SectorLON Exchange
Market Cap£877.82M£447.83M£5.33B£2.62B
Dividend Yield0.77%1.33%5.21%5.05%
P/E Ratio19.615.6826.71129.34
Price / Sales0.2914.72386.13221,585.85
Price / Cash9.979.9738.2528.03
Price / Book2.212.216.773.79
Net Income£51.04M£51.04M£3.23B£5.88B
7 Day Performance0.21%-0.19%1.80%0.62%
1 Month Performance18.99%0.82%11.10%22.12%
1 Year Performance26.88%-2.81%17.11%120.95%

Uniphar Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
UPR
Uniphar
0.7577 of 5 stars
GBX 282
-1.4%
GBX 310
+9.9%
+24.8%£877.82M£3.03B19.613,000
UDG
UDG Healthcare
N/AN/AN/AN/A£2.72B£1.25B42.489,000
BTG
BTG
N/AN/AN/AN/A£3.26B£914.10M29.474,690
ABC
Abcam
N/AN/AN/AN/A£2.81B£350.40M20,433.331,650Gap Up
High Trading Volume
HCM
HUTCHMED
N/AGBX 211
-1.4%
N/A-32.4%£2.29B£771.01M-53.851,760News Coverage
High Trading Volume
GNS
Genus
0.8659 of 5 stars
GBX 2,095.03
-1.2%
GBX 2,150
+2.6%
+10.8%£1.37B£666.67M173.66480News Coverage
Gap Down
INDV
Indivior
1.6901 of 5 stars
GBX 846
+0.1%
GBX 1,650
+95.0%
-36.2%£1.32B£1.40B-701.461,000News Coverage
ONT
Oxford Nanopore Technologies
2.419 of 5 stars
GBX 135.29
+0.7%
GBX 233.33
+72.5%
+21.2%£1.28B£184.78M-7.281,281Gap Up
CLIN
Clinigen Group
N/AN/AN/AN/A£1.23B£565.60M64.691,000
EMIS
EMIS Group
N/AN/AN/AN/A£1.23B£176.86M4,085.111,560News Coverage
VEC
Vectura Group
N/AN/AN/AN/A£1.01B£190.60M8.209,200

Related Companies and Tools


This page (LON:UPR) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners